Published in Obstet Gynecol on December 01, 2009
Cervical cancer screening among young adult women in the United States. Cancer Epidemiol Biomarkers Prev (2013) 1.22
Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine. Vaccine (2011) 1.10
Screening: HPV testing for cervical cancer: the good, the bad, and the ugly. Nat Rev Clin Oncol (2010) 0.89
Changes to cervical cancer prevention guidelines: effects on screening among U.S. women ages 15-29. Prev Med (2012) 0.81
Age at first intercourse and subsequent sexual partnering among adult women in the United States, a cross-sectional study. BMC Public Health (2015) 0.80
Teenage cervical screening in a high risk American population. Cytojournal (2011) 0.79
Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87
Dissemination of Evidence-based Practice Center reports. Ann Intern Med (2005) 2.05
Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med (2015) 1.63
Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. Cancer (2010) 1.53
Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt) (2012) 1.28
Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol Oncol (2009) 1.12
Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? Gynecol Oncol (2008) 1.09
Use of family planning and related medical services among women aged 15-44 in the United States: National Survey of Family Growth, 2006-2010. Natl Health Stat Report (2013) 1.01
Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (2008) 0.98
Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis. Gynecol Oncol (2007) 0.94
Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. Obstet Gynecol (2006) 0.91
Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness. Obstet Gynecol (2010) 0.89
Prevalence and timing of oral sex with opposite-sex partners among females and males aged 15-24 years: United States, 2007-2010. Natl Health Stat Report (2012) 0.86
Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. Gynecol Oncol (2007) 0.85
Liquid-based Papanicolaou smears without a transformation zone component: should clinicians worry? Obstet Gynecol (2002) 0.84
Chapter 10: deciding whether to complement a systematic review of medical tests with decision modeling. J Gen Intern Med (2012) 0.84
Changes to cervical cancer prevention guidelines: effects on screening among U.S. women ages 15-29. Prev Med (2012) 0.81
Single Health System Adherence to 2012 Cervical Cancer Screening Guidelines at Extremes of Age and Posthysterectomy. Obstet Gynecol (2017) 0.75
Behavioral and community correlates of adolescent pregnancy and Chlamydia rates in rural counties in Minnesota. J Community Health (2015) 0.75
Human Immunodeficiency Virus (HIV)- and Non-HIV-Associated Immunosuppression and Risk of Cervical Neoplasia. Obstet Gynecol (2017) 0.75
Predictors of Pertussis Polymerase Chain Reaction Positive Results in Minnesota, 2005-2009. Pediatr Infect Dis J (2015) 0.75
Birth Expectations of U.S. Women Aged 15-44. NCHS Data Brief (2016) 0.75
Adding decision models to systematic reviews: informing a framework for deciding when and how to do so. Value Health (2013) 0.75